Development and Clinical Translation of neuroinflammation-targeted Systemic Dendrimer Nanomedicines

19 September 2023 16:00 - 16:30

  • Inflammation plays a central role in the pathogenesis of many disorders – selective targeting of inflammatory cells may provide a powerful tool to improve therapeutic window in humans
  • Hydroxyl dendrimers enable systemic targeting of reactive inflammatory cells in the brain, eye and tumors, without a need for ligand or antibodies.
  • Cell-targeted dendrimer therapies produce significant efficacies in multiple preclinical models of neuroinflammatory and ocular disorders.
  • Early Phase 1 and Phase 2 trials of dendrimer-drug conjugates showed that lead candidates are safe in humans and produce significant benefits in patients with severe COVID-19, with Phase 2 trials for systemic wet AMD treatments ongoing.

Kannan Rangaramanujam, Arnall Patz Distiniguished Professor of Ophthalmology/Co-director, Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins Medicine